These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 7819892)

  • 1. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.
    Cozzi Lepri A; Pezzotti P; Dorrucci M; Phillips AN; Rezza G
    BMJ; 1994 Dec; 309(6968):1537-42. PubMed ID: 7819892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study.
    Phillips AN; Pezzotti P; Lepri AC; Rezza G
    AIDS; 1994 Sep; 8(9):1299-305. PubMed ID: 7802984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
    Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
    AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS?
    Lindbäck S; Broström C; Karlsson A; Gaines H
    BMJ; 1994 Dec; 309(6968):1535-7. PubMed ID: 7819891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users.
    Prins M; Hernández Aguado IH; Brettle RP; Robertson JR; Broers B; Carré N; Goldberg DJ; Zangerle R; Coutinho RA; van den Hoek A
    AIDS; 1997 Nov; 11(14):1747-56. PubMed ID: 9386810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
    Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
    Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study.
    Dorrucci M; Rezza G; Vlahov D; Pezzotti P; Sinicco A; Nicolosi A; Lazzarin A; Galai N; Gafà S; Pristerà R
    AIDS; 1995 Jun; 9(6):597-604. PubMed ID: 7662199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. HIV Italian Seroconversion Study Group.
    Pezzotti P; Phillips AN; Dorrucci M; Lepri AC; Galai N; Vlahov D; Rezza G
    BMJ; 1996 Sep; 313(7057):583-6. PubMed ID: 8806246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study.
    Prins M; Veugelers PJ
    AIDS; 1997 Apr; 11(5):621-31. PubMed ID: 9108944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II.
    AIDS; 1994 Jul; 8(7):923-33. PubMed ID: 7946101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis.
    Hendriks JC; Satten GA; van Ameijden EJ; van Druten HA; Coutinho RA; van Griensven GJ
    AIDS; 1998 Aug; 12(12):1537-44. PubMed ID: 9727576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group.
    Alliegro MB; Dorrucci M; Phillips AN; Pezzotti P; Boros S; Zaccarelli M; Pristerà R; Rezza G
    Arch Intern Med; 1997 Dec 8-22; 157(22):2585-90. PubMed ID: 9531227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. The Italian Seroconversion Study.
    AIDS; 1992 Apr; 6(4):421-6. PubMed ID: 1616637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired immunodeficiency syndrome (AIDS) risk in recent and long-standing human immunodeficiency virus type 1 (HIV-1)-infected patients with similar CD4 lymphocyte counts.
    Phillips AN; Sabin CA; Elford J; Bofill M; Janossy G; Lee CA
    Am J Epidemiol; 1993 Nov; 138(10):870-8. PubMed ID: 7901990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.
    Prins M; Sabin CA; Lee CA; Devereux H; Coutinho RA
    AIDS; 2000 Aug; 14(12):1829-37. PubMed ID: 10985321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.
    Maas JJ; Dukers N; Krol A; van Ameijden EJ; van Leeuwen R; Roos MT; de Wolf F; Coutinho RA; Keet IP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):254-9. PubMed ID: 9803967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion.
    Touloumi G; Karafoulidou A; Gialeraki A; Katsarou O; Milona I; Kapsimali V; Mandalaki T; Hatzakis A
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):89-97. PubMed ID: 9732075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?
    Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration)
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):158-65. PubMed ID: 11588510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion.
    Spijkerman IJ; Langendam MW; Veugelers PJ; van Ameijden EJ; Keet IP; Geskus RB; van den Hoek A; Coutinho RA
    Epidemiology; 1996 Nov; 7(6):571-7. PubMed ID: 8899381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.